Cure.’s Post

According to the Cystic Fibrosis Foundation, approximately 30,000 people in the US have CF . Treatment costs for CF vary depending on the severity of the disease and the specific needs of the patient. However, estimates suggest an annual cost per patient can range from $100,000 to $200,000. This yields a potential market size of $4.5B and many opportunities for research and development. Keep following us for more news and updates. Thanks! https://lnkd.in/gecw-JQ4 #CysticFibrosisAwareness #FightCF #CFCommunity #CysticFibrosisMarket #CFResearch #MedTechInnovation #RareDiseaseResearch #ClinicalTrials #PharmTech #HealthcareCosts #PatientAdvocacy #InvestingInHealth #MakingADifference #StayTuned

https://lnkd.in/gSPGdUBn Key Insights: • Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), and PL are exceptionally rare diseases causing premature aging, hastening mortality in young patients • Worldwide, there are approximately 400-450 children affected by Progeria, emphasizing its rarity and the urgent need for targeted treatments Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #foundation #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

Top 5 healthcare moments of 2023 From a healthcare perspective, 2023 was all about a changing of the guard after years of operating in a pandemic mindset. COVID-19 transitioned from pandemicity to endemicity and as such, industry leaders were able to shift their focus to other healthcare priorities. This coincided with the unprecedented rise of GLP-1 drugs for treating diabetes and obesity, numerous major pharma and biotech deals as well as the historic approval of an Alzheimer’s disease treatment. Below are the top five healthcare moments of 2023.

Diabetes Digital Therapeutics Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels, which can lead to a range of complications if left unmanaged. Digital therapeutics for diabetes have emerged as a promising solution to address the growing burden of this condition. RAVCARE's innovative platform combines cutting-edge technology, personalized coaching, and evidence-based interventions to empower patients and improve clinical outcomes. Learn more at https://lnkd.in/exGAzvhR #diabetes #prediabetes #DigitalTherapeutics

Today, we are going to talk about the science behind omeprazole, a common heartburn medication, and how it has potential anticancer benefits. https://lnkd.in/e9z39FPs

Get free of DIABETES to avoid great risk of CANCER. It is possible ONLY IF you get rid of sugar medicines (metformins etc.) and Insulin through an evidence-based medical solution.

Patient #Adherence remains a major concern within #HeartDisease treatment and that problem may increase when multiple therapies are prescribed. A 2022 study in the medical journal ESC Heart Failure, examining a Norwegian national cohort from 2014-2020, shows only 42% of heart failure patients adhered to dual therapy, and a mere 5% to triple therapy. These data highlight a critical area for improvement, and the authors call for #pharma and #digitalhealth sectors to innovate in enhancing adherence, crucial for better heart disease outcomes. Read the study for more ways to help boost adherence, including connecting with digital health platforms: https://lnkd.in/grb-CEHt #AmericanHeartMonth

A panel of experts have developed new guidelines for optimizing the use of #cannabidiol (#Epidiolex) in treating #seizures linked to tuberous sclerosis complex, Dravet syndrome, and Lennox–Gastaut syndrome. These guidelines, based on both published data and real-world experience, aim to enhance patient outcomes. Read more: https://brnw.ch/21wLMfR #RareDisease #SeizureManagement

We all know that an ounce of prevention is worth a pound of cure, but how often do we see this in action in the medical field? This is why I’m really interested in how GLP-1 agonists (obesity and type 2 diabetes drugs from Novo Nordisk and Eli Lilly and Company) will shape our healthcare system. This is a very special class of drugs which not only provide a treatment, but also significant prevention. Obesity is linked to 40%+ of cancers, and heightens risk for many more diseases our there. With GLP-1s treating obesity, I’m confident that their impact will be massive. This new development reminds me of when statins first hit the market. Statist have had a huge impact on our healthcare system and patients, with approximately 92 million people having used them in 2018-2019 [1]. Here’s the kicker though - unlike statins, which help prevent heart disease and stroke, GLP-1s promise to reduce nearly every leading cause of death on the US. I'm not just excited; I'm confident that GLP-1s will surpass statins in revolutionizing patient care while generating unprecedented revenue. Do you agree with my views on GLP-1s? Drop a comment.

Clinical decision-making for patients with inflammatory bowel disease can be complex. Learn how Mayo Clinic Laboratories' infliximab/adalimumab panel takes a proactive approach for patients with IBD. https://bit.ly/3JJeJM6